Common drugs for diabetes and weight loss can have an unexpected side effect.
Bulp-1 Bulp-1 receptors (GLP-1) is linked to glucagon, which is used to treat diabetes and/or obesity type 2, with vision problems in a small study at the University of British Columbia.
Some common GLP-1 drugs include OzemPIC and Wegovy, which contain semaglutide as an active ingredient, mounjaro and Zepbound, which contains tirzepatide.
The study indicates that weight loss may help him drinking this
In the study, nine patients using GLP-1 developed “complications of eyes”, according to researchers. The average age of patients was 57.4 years, according to the results of the study.
Bulp-1 Bulp-1 stimuli, which is used to treat type 2 and obesity diabetes, was linked to vision problems in a small study. (Istock)
Seven patients suffer from illegal anterior nerve nerves (NAION), causing visual loss in one eye.
One of the patient was infected with bilateral papilloma, which includes nerves of visual swelling that could cause poor vision, and another had acute central hamx, which leads to a blind spot in the retina.
OzemPIC’s health benefits continue to grow, but do you deserve risks?
All patients had a history of type 2 diabetes, hyperplasia (high blood or blood fats), high blood pressure and/or sleep apnea.
The results were published in ophthalmology.
“In one of the cases offered, the patient was taking medications for weight loss and had no previous history of diabetes (which could also be linked to the condition).” British Colombia told Fox News Digital.
The doctor (non -photographer) emphasized that these drugs should be considered only under the auspices of a health care professional and that “a good and consistent follow -up to dose adjustments while monitoring side effects” is crucial. (Istock)
“In another case, when the drug was stopped and returned, the condition appeared again, which strengthened a causal association.”
Ziad Alves, the clinical epidemic at the University of Washington in St. Louis, did not participate in the study but participated in his comments on the results.
“This is a very small study and has not been controlled-which means that it did not include people who do not use the GLP-1 drugs,” he told Fox News Digital.
“The GLP-1 story is still written-we learn something new about these medications every day.”
“This makes it impossible to know if the eye problems are caused by these medications.”
However, the doctor pointed out that “the GLP-1 story is still written-and we learn something new about these medications every day. The results should be followed in this study.”
Seven patients in the study developed unconventional optic neuropathy (NAION), causing visual loss in one eye. (Istock)
Eminan, the author of the main study, also approved the limits of the study.
“This data was derived from a series of individual cases and it was not a epidemic study,” he said. “However, another recent epidemic study also confirmed an increase in risk.”
The researchers say the body mass index is a wrong way to measure obesity.
Al -aly has called for the great studies that it controls-including people who take the drug and a monitoring group of people who do not use the drug-to assess the long-term health effects of these drugs, including eye problems.
“Meanwhile, for people who may be at risk of vision problems, or who are already visible problems, it is advised to be cautious,” he added. “People should discuss with their doctors to determine whether the GLP-1 is the appropriate drug for them.”
The doctor told Fox News Digital: “This is a very small study and has not been controlled-which means that it did not include people who do not use GLP-1 medications,” the doctor told Fox News Digital. (Istock)
Imainan chanted this warning.
“Those who take these medications for diabetes may continue to take them for their cardiovascular benefits, but be aware of the signs of NAION,” he advised.
“The healthy individuals who take them may want to lose a few pounds for an event to carefully evaluate the risk in exchange for the benefits of taking these medications.”
“Most of the side effects seem to be resolved when stopping the drug.”
Dr. Seth Kipnes, the medical director of obesity and robotic surgery at the medical center of the University of Hakesak Meridien Jersey Shore, indicated that there are “rare and unusual side effects” of this category of medicines, but he believes that vision changes seem more relevant to sugar in rapidly caused blood. For medicines from the same medicines.
Click here to get the Fox News app
“We have encouraged any patients taking these types of medications to report any unusual symptoms of described doctors,” Kibinsa, who also did not participate in the research, told Fox News Digital.
“Most of the side effects seem to be resolved when stopping the drug.”
Click here to register in our health newsletter
Kipnis emphasized that these drugs should be taken only under the auspices of a health care professional and that “a good and consistent dose adjustment with monitoring of side effects” is crucial.
When connected by Fox News Digital, Novo Nordisk (Ozmpic and Wegovy) presented the following statement.
“Those who take these medications for diabetes may continue to take them for their cardiovascular benefits, but be aware of the signs of NAION,” the doctor advised. (Istock)
“NAIOH is a very rare disease of the eye, not a harmful reaction to the drugs that were marketed from Semaglutide (Ozmpic®, Rybelsus®nd Wegovy®) according to the approved signs. After a comprehensive evaluation of studies from the University of South, Novo Nordisk sees that Denmark and Nofu Nordisk are in internal safety He believes that the well -known side appearance of the risks of the dirglotide remains unchanged. “
The company also noticed that eye conditions are “well -known diseases” for people with diabetes.
For more health articles, visit www.foxnews.com/health
“Any decision must be taken to start treatment with prescription medications only in consultation with a healthcare professional who must evaluate an atrocity for the patient concerned, which increases the benefits of treatment with potential risks,” Novo Nordsk added.